Amarantus Reports Third Quarter 2013 Financial Results and Development Progress
Company Will Host Investor Update Call on Monday November 18, 2013 at 4:00 PM
San Francisco Calif., November 14, 2013 –Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today reported financial results and development progress for the third quarter and nine-month periods ended September 30, 2013.
Amarantus reported a net loss for the third quarter of 2013 of $2,025,512 or $0.00 per share as compared to a net loss of $564,379 or $0.00 per share for the third quarter of 2012. The Company reported a net loss for the nine months ended September 20, 2013 of $5,783,685 or ($0.01) per share as compared to a net loss of $2,871,643 or ($0.03) per share for the same period in 2012.
On October 1, 2013 the Company closed on an additional $1.6 million in gross proceeds from its previous private placement of convertible debentures and warrants, bringing total gross proceeds from the private placement to $3.0 million. Cash and cash equivalents as of November 14, 2013, which are not reflected in the third quarter results, currently total approximately $1.7 million, which the Company intends to use as follows:
| 1. | Complete the first LymPro clinical performance study; |
| 2. | Complete the reprioritization of MANF and complete additional IND-enabling work; |
| 3. | Allow the Company to operate through the first half of 2014; |
| 4. | Complete the in-licensure of certain intellectual property. |
The Company also has the potential to raise up to an additional $5 million through the exercise of the warrants from the transaction, of which there can be no assurance, which would allow the Company to commercialize LymPro, file an IND for MANF in an orphan indication and initiate first-in-man studies, while operating into 2015.
Gerald E. Commissiong, President & CEO of Amarantus stated, “2013 has proven to be a very important year for Amarantus so far. With cash on hand from our recent funding we are now able to further the scientific development of our programs through key milestones that will allow the Company to unlock the underlying value inherent in our development programs. I am happy to report that we are moving ahead with clinical studies for LymPro to support its subsequent commercial launch, and we are very pleased with the reception we have received to date from key opinion leaders in the field who recognize its potential. The orphan indication data for MANF is providing an opportunity for a potentially reduced time to commercialization and we are thrilled to add Dr. David Lowe and his team to assist us with the reprioritization and execution phases that endeavor. We are uniquely positioned in the field of MANF product development, given extensive patent portfolio, and we continue to be extremely pleased with the interest MANF is garnering in the scientific community. As we move forward, Amarantus are focused on developing strong relationships with key medical centers and research organizations throughout the world as we continue to advance MANF and LymPro further down their development paths.”
Quarterly and Recent Highlights:
| · | Amarantus and Brewer Sports Announce 2nd #C4CT Concussion Awareness Summit Surrounding Super Bowl XLVIII |
| · | David A. Lowe, PhD Appointed to Board of Directors |
| · | Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco |
| · | Positive Analytical Performance Data for LymPro Test(R) for Alzheimer's Disease |
| · | Amarantus Enters Into Letter of Intent With Renishaw for Convection-Enhanced Delivery of MANF in Parkinson's Disease |
| · | F. Randall Grimes, MBA Appointed as Director of Sponsored Research |
| · | Closing of Private Placement Raising a Total of Approximately $3 Million |
| · | Dr. Colin Bier Appointed to Advisory Board for LymPro Commercialization |
| · | Positive Orphan Data for MANF in Retinitis Pigmentosa |
Conference Call Information
Management will host a conference call on Monday, November 18, 2013 at 4:00 PM. ET to provide updates and address investor questions regarding general business developments. Participants will include President & CEO Gerald Commissiong, newly appointed director Dr. David Lowe and corporate advisor Dr. Adam Simon. Interested parties may participate by dialing877-737-7051, (International): 201-689-8878approximately five minutes before the call start time. A replay of the call will be available starting on November 19, 2013 and through December 14, 2013. Interested parties may access the replay by dialing1-877-660-6853 201-612-7415(International) and entering conference ID number13572913.
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer’s disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”). For further information please visitwww.Amarantus.com, or connect with the Company onFacebook,LinkedIn,Twitter andGoogle+.
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements.” These forward-looking statements generally are identified by the words believes,” project,” expects,” anticipates,” estimates,” intends,” strategy,” plan,” may,” will,” would,” will be,” will continue,” will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor/Media Contacts
Russell Miller, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408.737.2734 x 109
ir@amarantus.com
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(A Development Stage Company)
CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2013 AND DECEMBER 31, 2012
| | | September 30, 2013
(Unaudited) | | | December 31, 2012 | |
| ASSETS | | | | | | | | |
| | | | | | | | | |
| CURRENT ASSETS: | | | | | | | | |
| Cash and cash equivalents | | $ | 1,015,121 | | | $ | 157,174 | |
| Prepaid expenses and other current assets | | | 487,767 | | | | 519,620 | |
| Total current assets | | | 1,502,888 | | | | 676,794 | |
| | | | | | | | | |
| PROPERTY AND EQUIPMENT – Net | | | — | | | | — | |
| | | | | | | | | |
| OTHER ASSETS | | | 646,143 | | | | 533,143 | |
| | | | | | | | | |
| TOTAL ASSETS | | $ | 2,149,031 | | | $ | 1,209,937 | |
| | | | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | | | | | | | | |
| | | | | | | | | |
| CURRENT LIABILITIES: | | | | | | | | |
| Accounts payable | | $ | 972,993 | | | $ | 2,596,848 | |
| Accrued liabilities | | | 176,986 | | | | 150,049 | |
| Debenture deposits | | | 587,500 | | | | — | |
| Related Party liabilities | | | 246,848 | | | | 222,083 | |
| Note Payable | | | 650,000 | | | | 740,000 | |
| Current portion of warrant liability | | | — | | | | 232,988 | |
| Current portion of derivative liability | | | 1,544,443 | | | | 26,893 | |
| Current portion of convertible promissory notes, net of debt discount | | | 485,936 | | | | 768,892 | |
| Total current liabilities | | | 4,664,706 | | | | 4,737,753 | |
| | | | | | | | | |
| COMMITMENTS AND CONTINGENCIES (Note 7) | | | | | | | | |
| | | | | | | | | |
| SERIES D CONVERTIBLE PREFERRED STOCK ($1,000 Stated Value; 1,300 shares designated and authorized; 1,299.327 shares issued and outstanding as of September 30, 2013) | | | 838,894 | | | | — | |
| | | | | | | | | |
| STOCKHOLDERS’ DEFICIT: | | | | | | | | |
| Convertible preferred stock, $0.001 par value - authorized, 10,000,000 shares, 250,000 shares designated as Series A, par value $0.001, -0- and 250,000 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively | | | — | | | | 250 | |
| Convertible preferred stock, $0.001 par value - authorized, 10,000,000 shares, 2,500,000 shares designated as Series B, par value $0.001, -0- shares issued and outstanding as of September 30, 2013 and December 31, 2012 | | | — | | | | — | |
| Convertible preferred stock, $0.001 par value - authorized, 10,000,000 shares, 750,000 shares designated as Series C, par value $0.001, 375,000 and -0- shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively | | | 375 | | | | — | |
| Common stock, $0.001 par value - authorized 1,000,000,000 shares; 530,403,308 and 342,516,931 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively | | | 530,404 | | | | 342,517 | |
| Additional paid-in capital | | | 13,760,385 | | | | 7,991,465 | |
| Deficit accumulated during the development stage | | | (17,645,733 | ) | | | (11,862,048 | |
| | | | | | | | | |
| Total stockholders’ deficit | | | (3,354,569 | ) | | | (3,527,816 | |
| | | | | | | | | |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | | $ | 2,149,031 | | | $ | 1,209,937 | |
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2013 AND 2012, AND
FOR THE PERIOD FROM JANUARY 14, 2008 (DATE OF INCEPTION) TO SEPTEMBER 30, 2013
| | | | | | | | | | | | | | | Period from | |
| | | Three Months
Ended | | | Three Months
Ended | | | Nine Months
Ended | | | Nine Months
Ended | | | January 14, 2008
(Date of Inception) | |
| | | September 30 , 2013 | | | September 30 , 2012 | | | September 30 , 2013 | | | September 30 , 2012 | | | to September 30, 2013 | |
| | | | | | | | | | | | | | | | |
| NET REVENUES | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | 415,996 | |
| | | | | | | | | | | | | | | | | | | | | |
| OPERATING EXPENSES: | | | | | | | | | | | | | | | | | | | | |
| Research and development | | | 288,431 | | | | 32,837 | | | | 1,427,025 | | | | 466,081 | | | | 3,446,140 | |
| General and administrative | | | 390,117 | | | | 558,668 | | | | 2,440,594 | | | | 2,423,370 | | | | 10,562,055 | |
| | | | | | | | | | | | | | | | | | | | | |
| Total costs and expenses | | | 678,548 | | | | 591,505 | | | | 3,867,619 | | | | 2,889,451 | | | | 14,008,195 | |
| | | | | | | | | | | | | | | | | | | | | |
| LOSS FROM OPERATIONS | | | (678,548 | ) | | | (591,505 | ) | | | (3,867,619 | ) | | | (2,889,451 | ) | | | (13,592,199 | ) |
| | | | | | | | | | | | | | | | | | | | | |
| INTEREST & OTHER INCOME (EXPENSE) | | | | | | | | | | | | | | | | | | | | |
| Interest Expense | | | (517,712 | ) | | | (197,577 | ) | | | (1,659,184 | ) | | | (485,141 | ) | | | (4,388,780 | ) |
| Other Income (Expense) | | | — | | | | (1,129 | )) | | | — | | | | (1,129 | ) | | | 75,823 | |
| Change in fair value of warrant & derivative liabilities | | | (829,252 | ) | | | 225,832 | | | | (256,882 | ) | | | 504,078 | | | | 625,292 | |
| | | | | | | | | | | | | | | | | | | | | |
| Total interest & other income (expense) | | | (1,346,964 | ) | | | 27,126 | | | | (1,916,066 | ) | | | 17,808 | | | | (3,687,665 | ) |
| | | | | | | | | | | | | | | | | | | | | |
| NET LOSS | | $ | (2,025,512 | ) | | $ | (564,379 | ) | | $ | (5,783,685 | ) | | $ | (2,871,643 | ) | | $ | (17,279,864 | ) |
| | | | | | | | | | | | | | | | | | | | | |
| NET LOSS PER SHARE, BASIC | | $ | (0.00 | ) | | $ | (0.00 | ) | | $ | (0.01 | ) | | $ | (0.03 | ) | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| COMMON SHARES OUTSTANDING - BASIC | | | 478,883,561 | | | | 113,190,278 | | | | 415,163,655 | | | | 99,478,308 | | | | | |
